Literature DB >> 16436754

Pulsatile delivery of clarithromycin alone or in combination with amoxicillin against Streptococcus pneumoniae.

Kimberly D Leuthner1, Chrissy M Cheung, Michael J Rybak.   

Abstract

We evaluated pulsatile dosing of clarithromycin and amoxicillin alone or combined against Streptococcus pneumoniae with various susceptibilities. When combined, pulsatile amoxicillin with clarithromycin was superior to either 8- or 12-h dosing against the intermediate strain and was identical for the susceptible strain. Pulse dosing of antimicrobials warrants further investigation.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16436754      PMCID： PMC1366876          DOI： 10.1128/AAC.50.2.813-816.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  5 in total

1.  Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant Staphylococcus aureus in an in vitro pharmacodynamic infection model.

Authors:  Vanthida Huang; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives.

Authors:  J Blaser
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

3.  Efficacy of pulsatile amoxicillin and clarithromycin dosing alone and in combination in a murine pneumococcal pneumonia model.

Authors:  Heather K Sun; Su Young Lee; Mary Anne Banevicius; Xiaoli Du; Dana Maglio; David P Nicolau
Journal:  J Antimicrob Chemother       Date:  2005-07-15       Impact factor: 5.790

4.  Pulsatile delivery of amoxicillin against Streptococcus pneumoniae.

Authors:  Raymond Cha; Michael J Rybak
Journal:  J Antimicrob Chemother       Date:  2004-10-14       Impact factor: 5.790

Review 5.  Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections.

Authors:  David Andes; Jack Anon; Michael R Jacobs; William A Craig
Journal:  Clin Lab Med       Date:  2004-06       Impact factor: 1.935
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.